title: Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease: results of an open, prospective, multicenter trial.
abstract: Glucocorticosteroids (GCS) are established in the treatment of active Crohn's ileitis and ileocolitis. Recently, the topical steroid budesonide was found to be effective in untreated patients with Crohn's disease (CD) causing less side effects than conventional GCS. No clinical data have been reported about the effects of switching from conventional GCS to budesonide in terms of side effects and disease activity. The primary aim of this study was to evaluate the development of side effects after switching from conventional GCS treatment to Eudragit L-coated budesonide (pH-modified release formulation) in patients taking 5-30 mg prednisolone equivalent per day for at least two weeks. In all, 178 patients with active CD (N = 88) or CD in remission during GCS treatment (N = 90) were included. Conventional GCS treatment was tapered down during a maximum of three weeks, with simultaneous intake of 3 x 3 mg budesonide. Thereafter, patients received 3 x 3 mg budesonide alone for six weeks. GCS-related side effects, disease activity and adverse events were documented at study entry and after 0, 2, 4, and 6 weeks of budesonide treatment. The percentage of patients with GCS-related side effects decreased from 65.2% (intention-to-treat-population) at entry to 43.3% (P < 0.0001) at the end of the trial. The total number of GCS-related side effects decreased significantly from 269 to 90. Of the patients who entered the study with active disease under conventional GCS therapy, 38.6% were in remission at the end of the study. Of the patients who entered the study with CD in remission, 78% stayed in remission after switching from conventinal GCS to budesonide. In conclusion, switching from conventional GCS treatment to budesonide leads to a significant reduction of GCS related side effects in patients with CD without causing rapid deterioration of the disease.
authors.affiliation: Klinikum Stuttgart, Krankenhaus Bad Cannstatt, Stuttgart, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Andus
authors.forename: V
authors.initials: V
authors.lastname: Gross
authors.forename: I
authors.initials: I
authors.lastname: Caesar
authors.forename: H J
authors.initials: HJ
authors.lastname: Schulz
authors.forename: H
authors.initials: H
authors.lastname: Lochs
authors.forename: W D
authors.initials: WD
authors.lastname: Strohm
authors.forename: M
authors.initials: M
authors.lastname: Gierend
authors.forename: A
authors.initials: A
authors.lastname: Weber
authors.forename: K
authors.initials: K
authors.lastname: Ewe
authors.forename: J
authors.initials: J
authors.lastname: Schölmerich
mesh_terms: D000284:Administration, Oral; D000328:Adult; D019819:Budesonide / Q000008:administration & dosage* / Q000009:adverse effects; D003424:Crohn Disease / Q000175:diagnosis* / Q000188:drug therapy*; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011336:Probability; D011446:Prospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D003692:Delayed-Action Preparations; D005938:Glucocorticoids; D019819:Budesonide